Fabian Dey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fabian Dey has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
Thomas Clairfeuille
Pharmaceutical Research and Early Development, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Grenzacherstrasse 124, Basel 4070, Switzerland
6 shared publicationsChristoph Bieniossek
Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
5 shared publications- Daniel Kahne
Department of Chemistry and Chemical Biology, Harvard University, Cambridge, USA
5 shared publications - Karanbir S. Pahil
Department of Chemistry and Chemical Biology, Harvard University, Cambridge, USA
5 shared publications - Kenneth Bradley
Departments of Immunology, Infectious Disease and Ophthalmology (I2O), Medicinal Chemistry and Lead Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
5 shared publications - Patrizio Mattei
Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
5 shared publications
Latest Publications
- 1 September 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (10) , 4872-4883
Dynlog P A Novel High-Throughput LC−MS Assay Quantifying Dynamic Lipophilicity and Chameleonicity of bRo5 Macrocyclic Peptides
The landscape of drug discovery has expanded beyond the traditional chemical space into the domain of large, flexible molecules, including beyond rule-of-five (bRo5) macrocyclic peptides (MCPs). Molecular chameleonicity, the capacity to dynamically adapt the conformation to the environment, balancing aqueous solubility and membrane permeability, has the potential to improve the oral bioavailability of these compounds. However, we lack experimental methods that quantify chameleonicity in a high-throughput manner. To address this need, we introduce DynlogP, a novel high-throughput, fully automated assay based on reverse-phase LC−MS that can quantify chameleonicity with minimal compound input. DynlogP measures calibrated lipophilicity under conditions promoting either solvent hydrogen bonding (log P70) or intramolecular hydrogen bonding (log P95), providing a quantitative measure of chameleonicity (Δlog P95−70) that is validated with NMR and molecular dynamics simulations. We profiled hundreds of molecules with DynlogP and demonstrate that chameleonicity is a common feature of MCPs. Machine learning models trained with DynlogP data allow for the prospective prediction of chameleonicity. Adoption and further refinement of DynlogP have the potential to empower compound prioritization and the design of orally bioavailable MCP-based therapeutics.
- 1 September 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (10) , 4872-4883
Dynlog P A Novel High-Throughput LC−MS Assay Quantifying Dynamic Lipophilicity and Chameleonicity of bRo5 Macrocyclic Peptides
The landscape of drug discovery has expanded beyond the traditional chemical space into the domain of large, flexible molecules, including beyond rule-of-five (bRo5) macrocyclic peptides (MCPs). Molecular chameleonicity, the capacity to dynamically adapt the conformation to the environment, balancing aqueous solubility and membrane permeability, has the potential to improve the oral bioavailability of these compounds. However, we lack experimental methods that quantify chameleonicity in a high-throughput manner. To address this need, we introduce DynlogP, a novel high-throughput, fully automated assay based on reverse-phase LC−MS that can quantify chameleonicity with minimal compound input. DynlogP measures calibrated lipophilicity under conditions promoting either solvent hydrogen bonding (log P70) or intramolecular hydrogen bonding (log P95), providing a quantitative measure of chameleonicity (Δlog P95−70) that is validated with NMR and molecular dynamics simulations. We profiled hundreds of molecules with DynlogP and demonstrate that chameleonicity is a common feature of MCPs. Machine learning models trained with DynlogP data allow for the prospective prediction of chameleonicity. Adoption and further refinement of DynlogP have the potential to empower compound prioritization and the design of orally bioavailable MCP-based therapeutics.
- 22 July 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (15) , 18665-18691
Structure-Based Design of Potent TLR7/8/9 Triple Antagonists: Overcoming High Tissue Distribution and Reactive Metabolite Liabilities
Sustained activation of endosomal Toll-like receptors (TLR) 7, 8, and 9 by self-nucleic acids is considered to be a key driver for autoimmune diseases, e.g., systemic lupus erythematosus (SLE). We report the discovery of a novel series of potent, orally bioavailable TLR7/8/9 triple antagonists featuring a unique “N-aryl-N” pharmacophore. Guided by TLR8 cocrystal structures and TLR7/9 homology models, we systematically optimized the series to balance pan-TLR potency with drug-like properties. Strategic modulation of lipophilicity and basicity successfully reduced the high volume of distribution (Vss) observed in mouse for early leads. Further compound optimization eliminated a reactive metabolite (GSH) liability. The resulting lead, compound 41, demonstrated robust dose-dependent inhibition of TLR7 and TLR9 pathways in mouse challenging models, supporting the potential of a TLR7/8/9 triple antagonist for treating autoimmune diseases.
- 22 July 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (15) , 18665-18691
Structure-Based Design of Potent TLR7/8/9 Triple Antagonists: Overcoming High Tissue Distribution and Reactive Metabolite Liabilities
Sustained activation of endosomal Toll-like receptors (TLR) 7, 8, and 9 by self-nucleic acids is considered to be a key driver for autoimmune diseases, e.g., systemic lupus erythematosus (SLE). We report the discovery of a novel series of potent, orally bioavailable TLR7/8/9 triple antagonists featuring a unique “N-aryl-N” pharmacophore. Guided by TLR8 cocrystal structures and TLR7/9 homology models, we systematically optimized the series to balance pan-TLR potency with drug-like properties. Strategic modulation of lipophilicity and basicity successfully reduced the high volume of distribution (Vss) observed in mouse for early leads. Further compound optimization eliminated a reactive metabolite (GSH) liability. The resulting lead, compound 41, demonstrated robust dose-dependent inhibition of TLR7 and TLR9 pathways in mouse challenging models, supporting the potential of a TLR7/8/9 triple antagonist for treating autoimmune diseases.
- 24 June 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (13) , 13532-13561
Orally Bioavailable Dopamine D1/D5 Receptor-Biased Agonists to Study the Role of β-Arrestin in Treatment-Related Dyskinesia in Parkinson’s Disease
Dopamine replacement therapies for Parkinson's disease often produce dyskinesias with long-term use. Published studies suggest that introducing β-arrestin signaling might be protective for dyskinesia. We advanced known noncatecholamine D1/D5 receptor G protein-biased agonists and found that removal of oxygen in the linker from published compounds limited β-arrestin recruitment, whereas introduction of nitrogen on the central o-phenyl linker favored β-arrestin recruitment and provided orally bioavailable compounds. Cryogenic electron microscopy suggested key receptor-ligand interactions influencing the different bias behaviors. We discovered compound 24, a D1/D5 receptor agonist with β-arrestin recruitment and properties for use in vivo. We compared 24 with tavapadon, which shows weak efficacy for β-arrestin signaling, in a rat model of Parkinson's disease with L-DOPA-induced dyskinesias. At particular doses, compound 24 produced efficacy comparable to L-DOPA, but with fewer concomitant dyskinesias. This first in vivo study suggests that β-arrestin may have a positive influence on reducing dyskinesias following acute administration.
- 24 June 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (13) , 13532-13561
Orally Bioavailable Dopamine D1/D5 Receptor-Biased Agonists to Study the Role of β-Arrestin in Treatment-Related Dyskinesia in Parkinson’s Disease
Dopamine replacement therapies for Parkinson's disease often produce dyskinesias with long-term use. Published studies suggest that introducing β-arrestin signaling might be protective for dyskinesia. We advanced known noncatecholamine D1/D5 receptor G protein-biased agonists and found that removal of oxygen in the linker from published compounds limited β-arrestin recruitment, whereas introduction of nitrogen on the central o-phenyl linker favored β-arrestin recruitment and provided orally bioavailable compounds. Cryogenic electron microscopy suggested key receptor-ligand interactions influencing the different bias behaviors. We discovered compound 24, a D1/D5 receptor agonist with β-arrestin recruitment and properties for use in vivo. We compared 24 with tavapadon, which shows weak efficacy for β-arrestin signaling, in a rat model of Parkinson's disease with L-DOPA-induced dyskinesias. At particular doses, compound 24 produced efficacy comparable to L-DOPA, but with fewer concomitant dyskinesias. This first in vivo study suggests that β-arrestin may have a positive influence on reducing dyskinesias following acute administration.
- 8 April 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (8) , 8497-8515
Discovery of Naphthyridinone Derivatives as Selective and Potent PKMYT1 Inhibitors with Antitumor Efficacy
PKMYT1 is a crucial regulator of the cell cycle, particularly involved in the G2/M transition through the inhibitory phosphorylation of CDK1, and is a promising therapeutic target for cancer therapy. Data mining in the Roche kinome screen database identified a hit characterized by 100% PKMYT1 inhibitory activity at a 10 μM concentration, which was further validated with a PKMYT1 enzymatic assay showing double-digit nanomolar potency. The hit featured a quinolinone central core and a phenol headgroup. The replacement of the problematic phenol headgroup with an indazole moiety induced a flip in the kinase hinge cysteine and glycine residues, resulting in a series of derivatives with enhanced potency, superior kinome selectivity, and no GSH flag. Further structural fine-tuning led to the discovery of compound 36, a novel, selective, and potent PKMYT1 inhibitor with favorable oral pharmacokinetic profiles and promising in vivo antitumor efficacy.
- 8 April 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (8) , 8497-8515
Discovery of Naphthyridinone Derivatives as Selective and Potent PKMYT1 Inhibitors with Antitumor Efficacy
PKMYT1 is a crucial regulator of the cell cycle, particularly involved in the G2/M transition through the inhibitory phosphorylation of CDK1, and is a promising therapeutic target for cancer therapy. Data mining in the Roche kinome screen database identified a hit characterized by 100% PKMYT1 inhibitory activity at a 10 μM concentration, which was further validated with a PKMYT1 enzymatic assay showing double-digit nanomolar potency. The hit featured a quinolinone central core and a phenol headgroup. The replacement of the problematic phenol headgroup with an indazole moiety induced a flip in the kinase hinge cysteine and glycine residues, resulting in a series of derivatives with enhanced potency, superior kinome selectivity, and no GSH flag. Further structural fine-tuning led to the discovery of compound 36, a novel, selective, and potent PKMYT1 inhibitor with favorable oral pharmacokinetic profiles and promising in vivo antitumor efficacy.
- Open Access
- 11 July 2024
- Published by Springer Nature in Nature
- Vol. 631 (8022) , E17
Author Correction: A novel antibiotic class targeting the lipopolysaccharide transporter
- 11 July 2024
- Published by Springer Nature in Nature
- Vol. 631 (8022) , E17
Open AccessAuthor Correction: A novel antibiotic class targeting the lipopolysaccharide transporter
- Open Access
- 11 July 2024
- Published by Springer Nature in Nature
- Vol. 631 (8022) , E18
Author Correction: A new antibiotic traps lipopolysaccharide in its intermembrane transporter
- 11 July 2024
- Published by Springer Nature in Nature
- Vol. 631 (8022) , E18
Open AccessAuthor Correction: A new antibiotic traps lipopolysaccharide in its intermembrane transporter
- Open Access
- 1 July 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Validating Small-Molecule Force Fields for Macrocyclic Compounds Using NMR Data in Different Solvents
Macrocycles are a promising class of compounds as therapeutics for difficult drug targets due to a favourable combination of properties: They often exhibit improved binding affinity compared to their linear counterparts due to their reduced conformational flexibility, while still being able to adapt to environments of different polarity. To assist in the rational design of macrocyclic drugs, there is need for computational methods that can accurately predict conformational ensembles of macrocycles in different environments. Molecular dynamics (MD) simulations remain one of the most accurate methods to predict ensembles quantitatively, although the accuracy is governed by the underlying force field. In this work, we benchmark four different force fields for their application to macrocycles by performing replica exchange with solute tempering (REST2) simulations of eleven macrocyclic compounds and comparing the obtained conformational ensembles to nuclear Overhauser effect (NOE) upper distance bounds from NMR experiments. Especially, the modern force fields OpenFF 2.0 and XFF yield good results, outperforming force fields like GAFF2 and OPLS/AA. We conclude that REST2 in combination with modern force fields can often produce accurate ensembles of macrocyclic compounds. However, we also highlight examples for which all examined force fields fail to produce ensembles that fulfill the experimental constraints.
- 1 July 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessValidating Small-Molecule Force Fields for Macrocyclic Compounds Using NMR Data in Different Solvents
Macrocycles are a promising class of compounds as therapeutics for difficult drug targets due to a favourable combination of properties: They often exhibit improved binding affinity compared to their linear counterparts due to their reduced conformational flexibility, while still being able to adapt to environments of different polarity. To assist in the rational design of macrocyclic drugs, there is need for computational methods that can accurately predict conformational ensembles of macrocycles in different environments. Molecular dynamics (MD) simulations remain one of the most accurate methods to predict ensembles quantitatively, although the accuracy is governed by the underlying force field. In this work, we benchmark four different force fields for their application to macrocycles by performing replica exchange with solute tempering (REST2) simulations of eleven macrocyclic compounds and comparing the obtained conformational ensembles to nuclear Overhauser effect (NOE) upper distance bounds from NMR experiments. Especially, the modern force fields OpenFF 2.0 and XFF yield good results, outperforming force fields like GAFF2 and OPLS/AA. We conclude that REST2 in combination with modern force fields can often produce accurate ensembles of macrocyclic compounds. However, we also highlight examples for which all examined force fields fail to produce ensembles that fulfill the experimental constraints.
- Open Access
- 10 January 2024
- Published by Springer Nature in Nature
- Vol. 625 (7996) , E27
Author Correction: A new antibiotic traps lipopolysaccharide in its intermembrane transporter
- 10 January 2024
- Published by Springer Nature in Nature
- Vol. 625 (7996) , E27
Open AccessAuthor Correction: A new antibiotic traps lipopolysaccharide in its intermembrane transporter
- Top Cited PapersOpen Access
- 3 January 2024
- Published by Springer Nature in Nature
- Vol. 625 (7995) , 566-571
A novel antibiotic class targeting the lipopolysaccharide transporter
Carbapenem-resistant Acinetobacter baumannii (CRAB) has emerged as a major global pathogen with limited treatment options1. No new antibiotic chemical class with activity against A. baumannii has reached patients in over 50 years1. Here we report the identification and optimization of tethered macrocyclic peptide (MCP) antibiotics with potent antibacterial activity against CRAB. The mechanism of action of this molecule class involves blocking the transport of bacterial lipopolysaccharide from the inner membrane to its destination on the outer membrane, through inhibition of the LptB2FGC complex. A clinical candidate derived from the MCP class, zosurabalpin (RG6006), effectively treats highly drug-resistant contemporary isolates of CRAB both in vitro and in mouse models of infection, overcoming existing antibiotic resistance mechanisms. This chemical class represents a promising treatment paradigm for patients with invasive infections due to CRAB, for whom current treatment options are inadequate, and additionally identifies LptB2FGC as a tractable target for antimicrobial drug development.
- 3 January 2024
- Published by Springer Nature in Nature
- Vol. 625 (7995) , 566-571
Top Cited PapersOpen AccessA novel antibiotic class targeting the lipopolysaccharide transporter
Carbapenem-resistant Acinetobacter baumannii (CRAB) has emerged as a major global pathogen with limited treatment options1. No new antibiotic chemical class with activity against A. baumannii has reached patients in over 50 years1. Here we report the identification and optimization of tethered macrocyclic peptide (MCP) antibiotics with potent antibacterial activity against CRAB. The mechanism of action of this molecule class involves blocking the transport of bacterial lipopolysaccharide from the inner membrane to its destination on the outer membrane, through inhibition of the LptB2FGC complex. A clinical candidate derived from the MCP class, zosurabalpin (RG6006), effectively treats highly drug-resistant contemporary isolates of CRAB both in vitro and in mouse models of infection, overcoming existing antibiotic resistance mechanisms. This chemical class represents a promising treatment paradigm for patients with invasive infections due to CRAB, for whom current treatment options are inadequate, and additionally identifies LptB2FGC as a tractable target for antimicrobial drug development.
- Top Cited PapersOpen Access
- 3 January 2024
- Published by Springer Nature in Nature
- Vol. 625 (7995) , 572-577
A new antibiotic traps lipopolysaccharide in its intermembrane transporter
Gram-negative bacteria are extraordinarily difficult to kill because their cytoplasmic membrane is surrounded by an outer membrane that blocks the entry of most antibiotics. The impenetrable nature of the outer membrane is due to the presence of a large, amphipathic glycolipid called lipopolysaccharide (LPS) in its outer leaflet1. Assembly of the outer membrane requires transport of LPS across a protein bridge that spans from the cytoplasmic membrane to the cell surface. Maintaining outer membrane integrity is essential for bacterial cell viability, and its disruption can increase susceptibility to other antibiotics2–6. Thus, inhibitors of the seven lipopolysaccharide transport (Lpt) proteins that form this transenvelope transporter have long been sought7–9. A new class of antibiotics that targets the LPS transport machine in Acinetobacter was recently identified. Here, using structural, biochemical and genetic approaches, we show that these antibiotics trap a substrate-bound conformation of the LPS transporter that stalls this machine. The inhibitors accomplish this by recognizing a composite binding site made up of both the Lpt transporter and its LPS substrate. Collectively, our findings identify an unusual mechanism of lipid transport inhibition, reveal a druggable conformation of the Lpt transporter and provide the foundation for extending this class of antibiotics to other Gram-negative pathogens.
- 3 January 2024
- Published by Springer Nature in Nature
- Vol. 625 (7995) , 572-577
Top Cited PapersOpen AccessA new antibiotic traps lipopolysaccharide in its intermembrane transporter
Gram-negative bacteria are extraordinarily difficult to kill because their cytoplasmic membrane is surrounded by an outer membrane that blocks the entry of most antibiotics. The impenetrable nature of the outer membrane is due to the presence of a large, amphipathic glycolipid called lipopolysaccharide (LPS) in its outer leaflet1. Assembly of the outer membrane requires transport of LPS across a protein bridge that spans from the cytoplasmic membrane to the cell surface. Maintaining outer membrane integrity is essential for bacterial cell viability, and its disruption can increase susceptibility to other antibiotics2–6. Thus, inhibitors of the seven lipopolysaccharide transport (Lpt) proteins that form this transenvelope transporter have long been sought7–9. A new class of antibiotics that targets the LPS transport machine in Acinetobacter was recently identified. Here, using structural, biochemical and genetic approaches, we show that these antibiotics trap a substrate-bound conformation of the LPS transporter that stalls this machine. The inhibitors accomplish this by recognizing a composite binding site made up of both the Lpt transporter and its LPS substrate. Collectively, our findings identify an unusual mechanism of lipid transport inhibition, reveal a druggable conformation of the Lpt transporter and provide the foundation for extending this class of antibiotics to other Gram-negative pathogens.